Search 

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological&Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has more than 8000 employees, 70% of which have the college degree or above.

Qilu pharmaceutical has always been sticking to the innovative development strategy. Guided by the market demand and the product innovation, Qilu has established extensive cooperation with domestic and foreign partners on a series of R&D projects. Qilu pays high attention to the introduction and cultivation of talents and has built a highly qualified R&D team with professional and efficient R&D capabilities, More than 100 national new drugs have been successfully developed, which constitutes the reasonable production line for the future development of Qilu. A number of technological achievements have obtained the national and provincial scientific & technological progress awards and created good social benefit.

Qilu Pharmaceutical has eight manufacturing sites covering an area of more than 2800,000 ㎡for finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The modern workshops are located in the manufacturing sites where the automatic production lines, key equipments and analytical instruments are imported from the leading suppliers all over the world. Now Qilu Pharmaceutical has been one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Qilu pharmaceutical has always been committing itself to providing the high-quality products to the patients and the society. Thanks to the integrated and stringent system of quality control and quality assurance, the company has been the leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.

Quan Capital is a healthcare-focused venture fund established by industry leaders. We are managing two USD funds with total AUMs over $400M.

We are a start-up company with a Phase III ready small molecule drug for the treatment of aortic valve stenosis. We

We licensed the drug from the Mayo Clinic and the drug has been part of the NIH's NCAT's Program in which they put in $5 million for our Phase I and Phase II clinical trials and Sanofi put in another $1 million for manufacturing.

We are raising a Series A round now and we welcome interest from Chinese investors and partners.

You can reach me at 858-205-5091.

Thanks.

----Randy Berholtz

We are working with life sciences companies to access China, which typically includes setting up, managing and funding local entities and/or finding local partners, investors and other resources. -;Current focus on cannabis/hemp, diagnostics, digital health.

RemeGen is committed to the discovery, development and commercialization of innovative and differentiated biological drugs. We strive to continuously create value through our clinical studies to develop products that meet the unmet clinical needs. We aim to become a global leader in the bio-pharmaceutical industry

Pharma and diagnostics

1994年成立上海市国资委直属投资公司

We are a group of angels selecting top companies to invest.

Sangel Capital provides venture capital and business finance to support high-tech enterprises in China and US. The firm seeks to invest in innovative startups in sectors including biopharma, diagnostics, medical devices, and biotech.
Sangel Capital was founded in 2010 and is based in Shenzhen, Beijing with additional offices in Suzhou and Chicago.